secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001213900-23-051702
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive shareholders elect all 4 director nominees, approve reverse stock split and equity plan amendment
--------------------------------------------------------------------------------

- Directors elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. John Ryan, Dr. Gaurav Aggarwal.
- Ratified Mayer Hoffman McCann as auditor for FY2023 (13,057,585 for, 30,776 against).
- Approved Nasdaq 20% issuance proposal (8,129,197 for, 236,958 against).
- Approved reverse stock split proposal (12,679,613 for, 412,810 against).
- Approved amendment and restatement of 2021 Omnibus Equity Incentive Plan (9,474,374 for, 959,587 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/ea180941-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-051702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer